The impact of targeting TRAF2 and NCK-interacting protein kinase (TNIK) on anti-tumor effect in small cell lung cancer
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Background
Small cell lung cancer (SCLC) is a highly lethal malignancy, with rapidly
acquired chemotherapy resistance. Some studies have reported that Wnt
signaling pathway activation promoted cell proliferation and was
correlated with chemo-resistance in SCLC (1-3). Additionally, our group
has demonstrated that cisplatin relapsed model generated high
mesenchymal subgroup using single-cell analysis (4). None of the
therapies targeting Wnt pathway components of the transmembrane and
the cytoplasm have been successful in a clinical application due to toxicity
and insufficient efficacy (5). However, targeting Wnt signaling inside the
nucleus has been drawing increasing attention as cancer therapeutics.
TRAF2 and NCK-interacting protein kinase (TNIK), which interacts with
downstream effectors, TCF4/β-catenin transcriptional complex, is an
essential activator of Wnt target genes (6). TINIK is highly expressed in
several cancers for cell proliferation, thus TNIK is expected as a novel
druggable target (7-11). On the other hand, the question remains whether
TNIK is a critical target in SCLC.

Outline of the role of TNIK
in Wnt/β-catenin pathway
Wnt ligand binds to its receptors
(Frizzled and LRP5/6), followed
by dishevelled (Dsh) protein
becomes activated. Dsh inhibits
GSK-3β/Axin/APC complex and
subsequently dephosphorylates βcatenin. Accumulated β-catenin in
cytoplasm moves to the nucleus
and binds to TCF4. TNIK is
required for activation of the
TCF4/β-catenin complex and
initiates transcription of Wnt target
genes.

Finding 1: A TNIK inhibitor significantly reduces cell viability of SCLC-N and
SCLC-P subtype.
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Fig 1. A novel TNIK inhibitor, NCB-0846 showed potent activity in SCLC-N
and SCLC-P cell lines. (A) IC50 values of NCB-0846 after 96h treatment in all
subtypes of SCLC cell lines. (B) Boxplots for IC50 values of NCB-0846 by
subtype. *, P<0.05, **, P<0.01
Finding 2: High levels of cMYC and TTF1 were strongly correlated with in
vitro sensitivity and resistance to the TNIK inhibitor.
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Experimental Design
• We evaluated susceptibility to a TNIK inhibitor, NCB-0846 in 29
human-derived SCLC cell lines using 96-hour proliferation assays.
• We correlated NCB-0846 IC50 values with proteomic profiling
(Reverse Phase Protein Array, RPPA) data.
• We reduced TNIK expression using siRNA against TNIK in human
SCLC cell lines.
• We assayed DNA damage protein changed by NCB-0846 using
western blot in human SCLC cell lines.

COI : I have no financial relationships to disclose.

A

B

C

D

Fig 3. TNIK inhibition reduces resistance to cisplatin in SCLC cells.
(A) Cell viability in cisplatin-resistant SCLC cells treated with either
scrambled siRNA or siRNA targeting TNIK. The cells were treated with
DMSO, cisplatin (1 µmol/L) and cisplatin (3 µmol/L) for 96 h. *, P<0.05, **,
P<0.01 (B) Western blotting of the SCLC cells with TNIK which were
treated with cisplatin (1 µmol/L) for 48h. (C) Cell viability determined after
treated with escalating doses of cisplatin, NCB-0846, and combination of
them for 96 h. (D) Western blotting of the cells treated with DMSO, cisplatin
(1 µmol/L) and/or NCB-0846 (500 nmol/L) for 48 h.
Summary and Future Directions

Hypothesis
We hypothesize that a TNIK inhibitor has potent anti-tumor effects in SCLC
and its promising biomarkers exist.

Finding 3: TNIK inhibition reinforces sensitivity to cisplatin in cisplatinresistant SCLC cells.

Fig 2. cMYC, ATR, and TTF1 are predictive biomarkers response to the
TNIK inihibitor in SCLC. (A) RPPA heatmap showing expression changes that
correlate with IC50 values in human SCLC cell lines. (B) Volcano plot of
Spearman coefficients (x-axis) versus p-values (y-axis). Labels were added for
proteins where p-values for association were below 0.05.
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• Our preclinical results indicate that cMyc and TTF-1, which negatively
correlated (12), are positive and negative predictive marker of the efficacy of
NCB-0846 in SCLC cell lines.
• Findings support TNIK inhibitors are selected for patients with SCLC
expressing cMYC high/TTF1 low, which is immunochemically
distinguishable (Fig. 4).
• Further studies should test combination of NCB-0846 and cisplatin in cMychigh/TTF1-low SCLC in vivo models.

Fig 4. Working model of how a
TNIK inhibitor may be selected
based on TTF1 and cMYC IHC.
Example TTF1 and cMYC IHC
from two archived SCLC tumor
samples on a neuroendocrine
TMA (scale bar = 100μm).
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